194 related articles for article (PubMed ID: 31206254)
21. Modulatory actions of o-coumaric acid on carcinogen-activating cytochrome P450 isozymes and the potential for drug interactions in human hepatocarcinoma cells.
Sen A; Terzioglu G; Atmaca P; Celik G; Ozgun O; Arslan S
Pharm Biol; 2015; 53(9):1391-8. PubMed ID: 25880144
[TBL] [Abstract][Full Text] [Related]
22. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
23. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
24. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
25. CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes.
Plonka W; Stork C; Šícho M; Kirchmair J
Bioorg Med Chem; 2021 Sep; 46():116388. PubMed ID: 34488021
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
[TBL] [Abstract][Full Text] [Related]
27. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
28. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels.
Ekstein D; Tirosh M; Eyal Y; Eyal S
Epilepsy Behav; 2015 Mar; 44():218-24. PubMed ID: 25771206
[TBL] [Abstract][Full Text] [Related]
29. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
[TBL] [Abstract][Full Text] [Related]
30. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer.
Marechal JD; Yu J; Brown S; Kapelioukh I; Rankin EM; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
Drug Metab Dispos; 2006 Apr; 34(4):534-8. PubMed ID: 16415122
[TBL] [Abstract][Full Text] [Related]
31. P450 enzyme expression patterns in the NCI human tumor cell line panel.
Yu LJ; Matias J; Scudiero DA; Hite KM; Monks A; Sausville EA; Waxman DJ
Drug Metab Dispos; 2001 Mar; 29(3):304-12. PubMed ID: 11181500
[TBL] [Abstract][Full Text] [Related]
32. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
33. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
34. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them.
Guo Z; Johnson V; Barrera J; Porras M; Hinojosa D; Hernández I; McGarrah P; Potter DA
Cancer Metastasis Rev; 2018 Sep; 37(2-3):409-423. PubMed ID: 30066055
[TBL] [Abstract][Full Text] [Related]
35. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.
van Schaik RH
Ther Drug Monit; 2004 Apr; 26(2):236-40. PubMed ID: 15228172
[TBL] [Abstract][Full Text] [Related]
36. Oral chemotherapy food and drug interactions: a comprehensive review of the literature.
Segal EM; Flood MR; Mancini RS; Whiteman RT; Friedt GA; Kramer AR; Hofstetter MA
J Oncol Pract; 2014 Jul; 10(4):e255-68. PubMed ID: 24756141
[TBL] [Abstract][Full Text] [Related]
37. Chimeric mice with humanized liver.
Katoh M; Tateno C; Yoshizato K; Yokoi T
Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
39. Cancer chemotherapy and drug metabolism.
Riddick DS; Lee C; Ramji S; Chinje EC; Cowen RL; Williams KJ; Patterson AV; Stratford IJ; Morrow CS; Townsend AJ; Jounaidi Y; Chen CS; Su T; Lu H; Schwartz PS; Waxman DJ
Drug Metab Dispos; 2005 Aug; 33(8):1083-96. PubMed ID: 16049130
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
